Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Corning Incorporated (GLW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Corning Incorporated — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.55 (market cap $5.07B), while Corning Incorporated trades at $167.45 (market cap $137.12B). The key difference: Corning Incorporated is far larger — about 27× ACADIA Pharmaceuticals Inc.'s market cap, and Corning Incorporated pays a 0.7% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | GLW | |
|---|---|---|
Market Cap | $5.07B | $137.12B |
Sector | Health | Technology |
52-Week High | $29.41 | $255.79 |
52-Week Low | $20.06 | $64.52 |
Enterprise Value | $4.19B | $144.00B |
Dividend Yield | — | 0.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.70, up 1.05% today, with a bullish technical trend and strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with $0.18 EPS, and raised its 2026 revenue outlook. Revenue grew to $1.07 billion in 2025, with net income surging to $391 million, reflecting a 36.49% margin. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.
The outlook remains positive given earnings momentum and product sales growth, though high valuation multiples and recent negative cash flow pose risks. Analyst consensus targets $33.89, implying ~14% upside, with 70% recommending Buy. Key risks include clinical trial outcomes and competitive pressures in the biopharma sector.
GLW trades at $166.95, up 5.84% in the last session, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $0.78, beating expectations, driven by 17% YoY core sales growth from optical and AI data center demand. Valuation ratios are elevated, with a P/E of 73.36 and P/S of 8.23, while profitability improved with a net income margin of 11.2% in 2025.
The outlook is supported by AI infrastructure growth and analyst optimism, with a consensus price target of $193.33 implying 16% upside. Risks include premium valuation sensitivity and execution challenges in scaling solar and optical segments. Cash flow is projected to turn positive in 2026, but debt-to-asset ratio remains elevated at 27.67%.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →
